Optimieren Sie Ihre Suche

  • Bücher (26)

bis

Benutzerdefinierte Preisspanne (EUR)

bis

Jane n winter (26 Ergebnisse)

Autor: 
Mit der Detailsuche verfeinern
  • Sprache: Spanisch

    Verlag: JUVENTUD,EDITORIAL, 2011

    8426138160 / 9788426138163

    • Hardcover

    Anbieter: Librerias Prometeo y Proteo, malaga, MA, SpanienLibrerias Prometeo y Proteo

    Verkäufer/-in mit 3 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 13,00

    EUR 90,00 Versand 
    Versand von Spanien nach USA

    Anzahl: 1 verfügbar

    Cartoné. Zustand: New. Zustand des Schutzumschlags: Nuevo. 01. Aquesta és una història real que succeeix a Colòmbia. El mestre Luis, un dia decideix carregar els seus dos rucs, lAlfa i en Beto, amb llibres per portar-los als nens que, per viure en allunyades zones rurals, no tenen accés a ells. Des de llavors, recor. LIBRO.…

  • Sprache: Englisch

    Verlag: ACM, 2007

    0015204391 / 9780015204396

    • Softcover

    Anbieter: Bulrushed Books, Moscow, ID, USABulrushed Books

    Verkäufer/-in mit 4 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Gebraucht - Befriedigend

    EUR 211,55

    EUR 8,15 Versand 
    Versand innerhalb von USA

    Anzahl: 1 verfügbar

    Zustand: Good. SHIPS FAST. RESCUED + RENEWED. Clean pages, light wear, and a strong binding make this a reliable, quality Good+ copy, kept in circulation through our Book Sustainability Program. No access codes or CDs.

  • Sprache: Englisch

    Verlag: Kluwer Academic Publishers, Boston., 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover

    Anbieter: Tiber Books, Cockeysville, MD, USATiber Books

    Verkäufer/-in mit 4 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Gebraucht - Gut

    EUR 233,57

    EUR 4,98 Versand 
    Versand innerhalb von USA

    Anzahl: 1 verfügbar

    Hardcover. Zustand: Very Good. 8vo, hardcover. No dj. Vg condition. Non-circulating ex-lib copy w/ label removed from endpaper, spine label removed, leaving outline; spine slightly faded (lettering fully visible), contents clean, binding tight. xiv, 416 p., illus.

  • Sprache: Englisch

    Verlag: ACM, 2007

    0015204391 / 9780015204396

    • Softcover

    Anbieter: Mispah books, Redhill, SURRE, Vereinigtes KönigreichMispah books

    Verkäufer/-in mit 4 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Gebraucht - Wie neu

    EUR 254,35

    EUR 29,97 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: 1 verfügbar

    paperback. Zustand: Like New. LIKE NEW. SHIPS FROM MULTIPLE LOCATIONS. book.

  • Sprache: Englisch

    Verlag: Springer, 2012

    1461379164 / 9781461379164

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Softcover

    Anbieter: GreatBookPrices, Columbia, MD, USAGreatBookPrices

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 332,06

    EUR 2,39 Versand 
    Versand innerhalb von USA

    Anzahl: 15 verfügbar

    Zustand: New.

  • Sprache: Englisch

    Verlag: Springer US, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover

    Anbieter: Buchpark, Trebbin, DeutschlandBuchpark

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Gebraucht - Sehr gut

    Sonderangebot

    Aktueller Preis: EUR 233,75

    EUR 105,00 Versand 
    Versand von Deutschland nach USA

    Anzahl: 1 verfügbar

    Zustand: Sehr gut. Zustand: Sehr gut | Seiten: 436 | Sprache: Englisch | Produktart: Bücher | Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come. Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/orexpand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors. Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed. The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigati.…

  • Weitere Bilder

    Sprache: Englisch

    Verlag: Springer, 2012

    1461379164 / 9781461379164

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Softcover

    Anbieter: preigu, Osnabrück, Deutschlandpreigu

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 274,85

    EUR 70,00 Versand 
    Versand von Deutschland nach USA

    Anzahl: 5 verfügbar

    Taschenbuch. Zustand: Neu. Blood Stem Cell Transplantation | Jane N. Winter | Taschenbuch | xv | Englisch | 2012 | Springer | EAN 9781461379164 | Verantwortliche Person für die EU: Springer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg, juergen[dot]hartmann[at]springer[dot]com | Anbieter: preigu.

  • Sprache: Englisch

    Verlag: Springer, 2012

    1461379164 / 9781461379164

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Softcover

    Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes KönigreichRia Christie Collections

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 354,61

    EUR 13,44 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: Mehr als 20 verfügbar

    Zustand: New. In English.

  • Sprache: Englisch

    Verlag: Springer, 2012

    1461379164 / 9781461379164

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Softcover

    Anbieter: GreatBookPrices, Columbia, MD, USAGreatBookPrices

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Gebraucht - Wie neu

    EUR 377,49

    EUR 2,39 Versand 
    Versand innerhalb von USA

    Anzahl: 15 verfügbar

    Zustand: As New. Unread book in perfect condition.

  • Sprache: Englisch

    Verlag: Springer, 2012

    1461379164 / 9781461379164

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Softcover

    Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 359,50

    EUR 35,00 Versand 
    Versand von Deutschland nach USA

    Anzahl: 1 verfügbar

    Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come. Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/orexpand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors. Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed. The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigation and for the clinical experiments.…

  • Sprache: Englisch

    Verlag: Springer, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover

    Anbieter: GreatBookPrices, Columbia, MD, USAGreatBookPrices

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 472,03

    EUR 2,39 Versand 
    Versand innerhalb von USA

    Anzahl: 15 verfügbar

    Zustand: New.

  • Sprache: Englisch

    Verlag: Springer, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover

    Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes KönigreichGreatBookPricesUK

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 522,73

    EUR 17,98 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: Mehr als 20 verfügbar

    Zustand: New.

  • Sprache: Englisch

    Verlag: Springer, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover

    Anbieter: California Books, Miami, FL, USACalifornia Books

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 547,48

    EUR 2,72 Versand 
    Versand innerhalb von USA

    Anzahl: Mehr als 20 verfügbar

    Zustand: New.

  • Sprache: Englisch

    Verlag: Springer, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover

    Anbieter: GreatBookPrices, Columbia, MD, USAGreatBookPrices

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Gebraucht - Wie neu

    EUR 565,32

    EUR 2,39 Versand 
    Versand innerhalb von USA

    Anzahl: 15 verfügbar

    Zustand: As New. Unread book in perfect condition.

  • Sprache: Englisch

    Verlag: Springer, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover

    Anbieter: GreatBookPricesUK, Woodford Green, Vereinigtes KönigreichGreatBookPricesUK

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Gebraucht - Wie neu

    EUR 561,55

    EUR 17,98 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: Mehr als 20 verfügbar

    Zustand: As New. Unread book in perfect condition.

  • Sprache: Englisch

    Verlag: Springer, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover

    Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes KönigreichRia Christie Collections

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 563,52

    EUR 15,38 Versand 
    Versand von Vereinigtes Königreich nach USA

    Anzahl: Mehr als 20 verfügbar

    Zustand: New. In English.

  • Sprache: Englisch

    Verlag: Kluwer Academic Publishers, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover

    Anbieter: Kennys Bookshop and Art Galleries Ltd., Galway, GY, IrlandKennys Bookshop and Art Galleries Ltd.

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 570,00

    EUR 9,50 Versand 
    Versand von Irland nach USA

    Anzahl: 15 verfügbar

    Zustand: New. This text seeks to convey the extent and significance of a current development in haematopoietic stem cell transplantation. Editor(s): Winter, Jane N. Series: Cancer Treatment and Research. Num Pages: 416 pages, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 235 x 155 x 23. Weight in Grams: 785. . 1997. Hardback. . . . . …

  • Sprache: Englisch

    Verlag: Springer US, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover

    Anbieter: AHA-BUCH GmbH, Einbeck, DeutschlandAHA-BUCH GmbH

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 534,88

    EUR 35,00 Versand 
    Versand von Deutschland nach USA

    Anzahl: 1 verfügbar

    Buch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come. Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/orexpand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors. Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed. The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigati.…

  • Sprache: Englisch

    Verlag: Kluwer Academic Publishers, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover

    Anbieter: Kennys Bookstore, Olney, MD, USAKennys Bookstore

    Verkäufer/-in mit 4 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 750,94

    EUR 9,52 Versand 
    Versand innerhalb von USA

    Anzahl: 15 verfügbar

    Zustand: New. This text seeks to convey the extent and significance of a current development in haematopoietic stem cell transplantation. Editor(s): Winter, Jane N. Series: Cancer Treatment and Research. Num Pages: 416 pages, biography. BIC Classification: MJCL. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly; (UU) Undergraduate. Dimension: 235 x 155 x 23. Weight in Grams: 785. . 1997. Hardback. . . . . Books ship from the US and Ireland. …

  • Sprache: Englisch

    Verlag: Springer, 2012

    1461379164 / 9781461379164

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Softcover
    • Print-on-Demand

    Anbieter: Brook Bookstore On Demand, Napoli, NA, ItalienBrook Bookstore On Demand

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 246,33

    EUR 6,80 Versand 
    Versand von Italien nach USA

    Anzahl: Mehr als 20 verfügbar

    Zustand: new. Questo è un articolo print on demand.

  • Sprache: Englisch

    Verlag: Springer US, 2012

    1461379164 / 9781461379164

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Softcover
    • Print-on-Demand

    Anbieter: moluna, Greven, Deutschlandmoluna

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 267,86

    EUR 48,99 Versand 
    Versand von Deutschland nach USA

    Anzahl: Mehr als 20 verfügbar

    Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances .…

  • Sprache: Englisch

    Verlag: Springer US Okt 2012, 2012

    1461379164 / 9781461379164

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Softcover
    • Print-on-Demand

    Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, DeutschlandBuchWeltWeit Ludwig Meier e.K.

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 320,99

    EUR 23,00 Versand 
    Versand von Deutschland nach USA

    Anzahl: 2 verfügbar

    Taschenbuch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come. Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/or expand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors. Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed. The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigation and for the clinical experiment 436 pp. Englisch.…

  • Sprache: Englisch

    Verlag: Springer, Springer Okt 2012, 2012

    1461379164 / 9781461379164

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Softcover
    • Print-on-Demand

    Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschlandbuchversandmimpf2000

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 320,99

    EUR 60,00 Versand 
    Versand von Deutschland nach USA

    Anzahl: 1 verfügbar

    Taschenbuch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come.Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/orexpand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors.Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed.The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigatiSpringer-Verlag KG, Sachsenplatz 4-6, 1201 Wien 436 pp. Engl.…

  • Sprache: Englisch

    Verlag: Springer US, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover
    • Print-on-Demand

    Anbieter: moluna, Greven, Deutschlandmoluna

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 399,55

    EUR 48,99 Versand 
    Versand von Deutschland nach USA

    Anzahl: Mehr als 20 verfügbar

    Gebunden. Zustand: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances .…

  • Sprache: Englisch

    Verlag: Springer US Mrz 1997, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover
    • Print-on-Demand

    Anbieter: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, DeutschlandBuchWeltWeit Ludwig Meier e.K.

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 481,49

    EUR 23,00 Versand 
    Versand von Deutschland nach USA

    Anzahl: 2 verfügbar

    Buch. Zustand: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come. Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/or expand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors. Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed. The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigation and for the clinical experiment 436 pp. Englisch.…

  • Sprache: Englisch

    Verlag: Springer US, Springer US Mär 1997, 1997

    0792342607 / 9780792342601

    Serie: Buch 92 von 180 - Cancer Treatment and Research

    • Hardcover
    • Print-on-Demand

    Anbieter: buchversandmimpf2000, Emtmannsberg, BAYE, Deutschlandbuchversandmimpf2000

    Verkäufer/-in mit 5 Sternen
    Verkäufer/-in kontaktieren

    Zustand: Neu

    EUR 481,49

    EUR 60,00 Versand 
    Versand von Deutschland nach USA

    Anzahl: 1 verfügbar

    Buch. Zustand: Neu. This item is printed on demand - Print on Demand Titel. Neuware -Blood Stem Cell Transplantation conveys the excitement that accompanies the newest developments in hematopoietic stem cell transplantation. Some of the applications that stand to impact this field most significantly are based on recent advances in the biological sciences, as demonstrated by the chapters on gene therapy, on the detection of minimal residual disease using molecular techniques, and on the use of radioimmunoconjugates targeting lymphoma and leukemia-associated antigens. Others are the results of clinical observations - e.g., the association between graft-versus-host- disease (GVHD) and durable remissions that have led to creative clinical experiments such as donor leukocyte infusions (DLI). Attempts to unravel the biological events that underlie the responses seen in patients with relapsed chronic myelogenous leukemia treated with DLI are likely to provide the basis for future refinements in this clinical approach. Hopefully, improved response rates and reduced toxicity will result. The power of the immunologic response in controlling malignant disease is underscored in the chapter on post-transplant immunotherapy. The complex immunologic process that results in clinical GVHD may be dissected and engineered to provide clinical benefits that include, in addition to its antineoplastic effects, the amelioration of its clinical manifestations. Better control of GVHD with less global immunosuppression will facilitate the use of mismatched and unrelated donors. This area of investigation perfectly illustrates the continued interplay between the laboratory and the clinic. The continued cross-fertilization of ideas between immunologists, molecular biologists and clinical investigators is likely to yield important advances in this field for years to come.Possible applications of stem cell transplantation continue to grow with the identification of alternative sources of stem cells and the potential to engineer and/orexpand the graft. Although the use of unrelated and mismatched donors continues to increase, the possibilities associated with umbilical cord blood transplantation are legion, especially if stem cells can be expanded ex vivo to provide grafts for full-sized adults. Using techniques in which contaminating malignant cells may be eliminated from autografts through positive selection, autologous transplantation may prove highly effective, especially when coupled with post-transplant immunotherapy. Some of these same methodologies have helped facilitate the use of autologous grafts for transplantation in patients with chronic myelogenous leukemia without allogeneic donors.Advances in the supportive care of transplant patients, including the pretransplant identification of those at risk from pulmonary complications and the use of cytokines to speed engraftment, have reduced morbidity and mortality to such a degree that it is appropriate to consider high-dose therapy and stem cell reconstitution in patients with nonmalignant diseases. The impressive advances that have occurred in transplantation for thalassemia are described by pioneers in their area of investigation. The burgeoning field of transplantation for autoimmune disorders, including its immunobiologic basis and soon-to- be-realized clinical potential, is also summarized. Continued progress in the use of high-dose therapy with stem cell rescue for the treatment of pediatric tumors, which derives in part from improved supportive care, is detailed.The sobering voice of the health care economists underscores the necessary limitations to our seemingly unbridled imagination. Cost- consciousness and financial know-how will need to be reflected in future study designs. Given the seemingly endless applications of our technology, strategies to insure its cost-effectiveness will be necessary. Continued financial support for laboratory investigatiSpringer Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 43.…